publication venue for
- Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA. 2023
- Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17. 2022
- Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. 2022
- Population-level impact of initiating pharmacotherapy and linking to care persons with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. 2022
- The Opioid Use Disorder Core Outcomes Set (OUD-COS) for treatment research: findings from a Delphi consensus study. 2022
- Community-based Naloxone Coverage Equity for the Prevention of Opioid Overdose Fatalities in Racial/Ethnic Minority Communities in Massachusetts and Rhode Island. 2021
- Illegal drug market responses to state recreational cannabis laws. 2021
- Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. 2021
- Trends in cannabis use among adults with children in the home in the United States, 2004-2017: impact of state-level legalization for recreational and medical use.. 116. 2021
- Medical marijuana laws are associated with increases in substance use treatment admissions by pregnant women.. 114. 2019
- Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose?. 114. 2019
- Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014.. 113. 2018
- E-cigarette price sensitivity among middle- and high-school students: evidence from monitoring the future.. 113. 2018
- Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.. 112. 2017
- The effect of potential electronic nicotine delivery system regulations on nicotine product selection.. 111. 2016
- Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population.. 111. 2015
- Understanding Americans' views on opioid pain reliever abuse.. 111. 2015
- Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.. 110. 2015
- Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy.. 105. 2010
- Ambient temperature and risk of death from accidental drug overdose in New York City, 1990-2006.. 105. 2010
- Extended cognitive behavior therapy for cigarette smoking cessation.. 103. 2008
- Overdose deaths attributed to methadone and heroin in New York City, 1990-1998.. 99. 2004
- Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98.. 98. 2003
- Sex differences in the effects of stressful life events on changes in smoking status.. 98. 2003
- HIV infection among victims of accidental fatal drug overdoses in New York City.. 92. 1997
- Medical marijuna laws: Response to Caputi.. 115. 2019
- Commentary on Barbosa et al. (2019): The value of using community simulation modeling to achieve HCV elimination targets in people who inject drugs.. 114. 2019
- The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. 2020